Abstract

Transcription factor nuclear factor kappa B (NF-?B) plays a major role in the pathogenesis of chronic inflammatory diseases in all organ systems. Despite its importance, NF-?B targeted drug therapy to mitigate chronic inflammation has had limited success in preclinical studies. We hypothesized that sex differences affect the response to NF-?B treatment during chronic inflammation in bone. This study investigated the therapeutic effects of NF-?B decoy oligodeoxynucleotides (ODN) during chronic inflammation in male and female mice.We used a murine model of chronic inflammation induced by continuous intramedullary delivery of lipopolysaccharide-contaminated polyethylene particles (cPE) using an osmotic pump. Specimens were evaluated using micro-CT and histomorphometric analyses. Sex-specific osteogenic and osteoclastic differentiation potentials were also investigated in vitro, including alkaline phosphatase, Alizarin Red, tartrate-resistant acid phosphatase staining, and gene expression using reverse transcription polymerase chain reaction (RT-PCR).Local delivery of NF-?B decoy ODN in vivo increased osteogenesis in males, but not females, in the presence of chronic inflammation induced by cPE. Bone resorption activity was decreased in both sexes. In vitro osteogenic and osteoclastic differentiation assays during inflammatory conditions did not reveal differences among the groups. Receptor activator of nuclear factor kappa ? ligand (Rankl) gene expression by osteoblasts was significantly decreased only in males when treated with ODN.We demonstrated that NF-?B decoy ODN increased osteogenesis in male mice and decreased bone resorption activity in both sexes in preclinical models of chronic inflammation. NF-?B signalling could be a therapeutic target for chronic inflammatory diseases involving bone, especially in males.

View details for DOI 10.1302/2046-3758.131.BJR-2023-0040.R3

View details for PubMedID 38194999